|
2025 KASL clinical practice guidelines for management of hepatitis C
|
Eun Sun Jang, Nae Yun Heo, Jae Yoon Jeong, Jung Gil Park, Do Seon Song, Eun Ju Cho, Chang Hun Lee, Jae Seung Lee, Jae Hyun Yoon, Seul Ki Han, Young Kul Jung
|
p. 1-52
|
|
|
|
|
|
Pediatric metabolic dysfunction–associated steatotic liver disease and the gut microbiome : from research landscape to targeted modulation
|
Lu Jiang, Lan-Duoduo Du, Jing Zeng, Hui-Kuan Chu, Zhong Peng, Jian-Gao Fan
|
p. 53-68
|
|
|
|
|
|
Tumor-based biomarkers and circulating tumor DNA for precision medicine in advanced hepatocellular carcinoma
|
Sabrina Sidali, Claudia Campani, Jihyun An, Ju Hyun Shim, Jean-Charles Nault
|
p. 69-90
|
|
|
|
|
|
Harnessing the microbiome : unveiling the influence of the gut microbiota on hepatobiliary cancer therapeutic strategies
|
Melody Yusong Li, Xue Qian Wu, Terence Kin Wah Lee
|
p. 91-126
|
|
|
|
|
|
Stratifying cholangiocarcinoma : tumor microenvironment, molecular drivers, and novel immunotherapeutic approaches
|
Cindy Xinqi Liu, Carmen Chak-Lui Wong
|
p. 127-155
|
|
|
|
|
|
Panomics in metabolic dysfunction-associated steatotic liver disease : unravelling the drivers of disease heterogeneity
|
Carlos José Pirola, Silvia Sookoian
|
p. 156-169
|
|
|
|
|
|
Incretin-based therapies for cardio-kidney-liver-metabolic disease : the role of the liver in the modern era of chronic disease management
|
Harendran Elangovan, Rohit Loomba, Mark Muthiah, Jörn Schattenberg, Ming Hua Zheng, Mazen Noureddin, Christos Mantzoros, Jacob George
|
p. 170-183
|
|
|
|
|
|
Targeting the innate immune system in treating hepatitis B : prospects for functional cure
|
Karen Cheuk-Ying Ho, Rex Wan-Hin Hui, Wai-Kay Seto, Man-Fung Yuen, Lung-Yi Mak
|
p. 184-199
|
|
|
|
|
|
RAB25/GCN1 signaling promotes endoplasmic reticulum stress to mediate alcohol-associated liver disease progression
|
Xue-Wen Liu, Zi-Bin Zhan, Ze-Hua Li, Yue Zhang, Xue-Yan Qiao, Xin-Ming Li, Xiang-Jing Liang, Kun-Hao Bai, Xian-Feng Xia, Fan-Hong Zeng, Yi Gao, Jun Weng
|
p. 200-220
|
|
|
|
|
|
Gut microbiota-mediated berberine metabolism ameliorates cholestatic liver disease by suppressing 5-hydroxytryptamine production
|
Dianji Tu, Cheng Lu, Junfeng Guo, Qiao Chen, Xin Li, Yingjie Wang, Lulu Cheng, Hongfei Jiang, Jincheng Jian, Yusong Ge ... [et al.]
|
p. 221-238
|
|
|
|
|
|
Bacteroides eggerthii ameliorates metabolic dysfunction-associated steatotic liver disease through host–microbe signaling and highlights 2-hydroxyisocaproate as a potential effector
|
Jiyi Choi, Moon Gyeong Yoon, Se Ha Jang, Geum Ok Baek, Hyun Sun Jung, Na-Rae Lee, Choong Hwan Lee, Ji Eun Han, Jae Youn Cheong, Jung Woo Eun, Soon Sun Kim
|
p. 239-257
|
|
|
|
|
|
Integrative multi-omics profiling identifies infiltrative hepatocellular carcinoma as an immunotherapy-resistant subtype with distinct molecular features
|
Won Suk Lee, Seonjeong Woo, Sung Hwan Lee, Gae Hoon Jo, Ilhwan Kim, Hyeyeong Kim, Chansik An, Sanghoon Jung, Gwangil Kim, Haeyoun Kang ... [et al.]
|
p. 258-275
|
|
|
|
|
|
Evaluating treatment response thresholds for cost-effective treatment in metabolic dysfunction-associated steatotic liver disease
|
Eileen L. Yoon, Jeong-Yeon Cho, Huiyul Park, Mimi Kim, Ji-Hyeon Park, Hye-Lin Kim, Dae Won Jun
|
p. 276-288
|
|
|
|
|
|
Histological severity and hepatic outcomes in patients with metabolic dysfunction-associated steatotic liver disease and discrepant FIB-4 and liver stiffness measurement
|
Joseph Rabbat, Boyu Yang, Hye Won Lee, Huapeng Lin, Emmanuel Tsochatzis, Salvatore Petta, Elisabetta Bugianesi, Masato Yoneda, Ming-Hua Zheng, Hannes Hagström ... [et al.]
|
p. 289-304
|
|
|
|
|
|
Comparative risk of fibrosis progression with sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitors in metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus with low-to-intermediate fibrosis
|
Jonggi Choi, Daniel Fulop, Vy H. Nguyen, Eric Przybyszewski, Jiunn Song, Allison Carroll, Megan Michta, Erik Almazan, Tracey G. Simon, Raymond T. Chung
|
p. 305-317
|
|
|
|
|
|
Novel near-infrared probe for monitoring lipid peroxidation-mediated viscosity change in ferroptotic hepatocytes
|
Le Bich Hang Pham, Taeeung Kim, Seoyoung Kim, Yun Seok Kim, Jiyeon Kim, Kyeongseon Kim, Hyeonwoo Lim, Wan Seob Shim, Byoungmo Kim, So-Yeol Yoo, Jae-Young Lee, Murim Choi, Won Kim, Keon Wook Kang, Jeeyeon Lee
|
p. 318-338
|
|
|
|
|
|
Aspirin and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease : nationwide cohort study with genetic risk analysis
|
Juhee Ahn, Moon Haeng Hur, Hyunjae Shin, Min Kyung Park, Sungho Won, Jeayeon Park, Yunmi Ko, Youngsu Park, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim
|
p. 339-352
|
|
|
|
|
|
Hypothyroidism and the risk of liver-related events in patients with metabolic dysfunction-associated steatotic liver disease
|
Xinrui Jin, Sherlot Juan Song, Jimmy Che-To Lai, Grace Lai-Hung Wong, Alice Pik-Shan Kong, Nana Peng, Xiang Xiao, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip
|
p. 353-367
|
|
|
|
|
|
(Research letter) Contemporary trends in extrahepatic mortality of chronic liver disease in the United States from 2014 to 2023
|
Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Aijaz Ahmed
|
p. 24-28
|
|
|
|
|
|
(Research letter) Early oxidative protein modifications and gut damage/leakiness contribute to drug-induced acute liver failure
|
Wiramon Rungratanawanich, Ying Qu, Andrew Holmes, Neil Kaplowitz, Byoung-Joon Song
|
p. 29-33
|
|
|
|
|
|
(Research letter) Non-contrast magnetic resonance imaging outperforms contrast-enhanced computed tomography in preoperative detection of hepatocellular carcinoma : a paired validation study
|
Laizhu Zhang, Weiwei Zong, Jialin Gao, Huan Li, Leizhou Xia, Xiaoli Mai, Jun Chen, Binghua Li, Decai Yu
|
p. 34-37
|
|
|
|
|
|
(Research letter) Distinct tumor immune microenvironment modulation by anti-PD-1/PD-L1, VEGF, and CTLA-4 blockade provides a rationale for triplet therapy in hepatocellular carcinoma
|
Hideki Iwamoto, Hironori Koga, Takumi Kawaguchi
|
p. 38-42
|
|
|
|
|
|
(Research letter) Fifteen-year impact of cholecystectomy on multiple organs
|
Ming Zheng
|
p. 43-46
|
|
|
|
|
|
(Research letter) Optimized MASH treatment eligibility cutoffs for MRE-measured liver stiffness and proton density fat fraction
|
Nana Owusu, Kyle Kalutkiewicz, Jiahui Li, Alina M. Allen, Rohit Loomba, Richard L. Ehman, Meng Yin
|
p. 47-51
|
|
|
|
|
|
(Correspondence) HCC predictors in routine practice for patients with chronic liver diseases : correspondence to editorial on “high SAFE scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic dysfunction associated steatotic liver disease”
|
Tung-Hung Su, Jia-Horng Kao
|
p. 52-54
|
|
|
|
|
|
Correspondence to editorial on “switching to besifovir in patients with chronic hepatitis B receiving tenofovir disoproxil fumarate: a randomized trial”
|
Hyung Joon Yim, Seong Hee Kang, Young Kul Jung, Jin Mo Yang
|
p. 55-57
|
|
|
|
|
|
Correspondence to editorial 1 on “Baveno Ⅵ-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”
|
Haiyu Wang, Jinjun Chen
|
p. 58-61
|
|
|
|
|
|
Correspondence to editorial 2 on “Baveno Ⅵ-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”
|
Haiyu Wang, Jinjun Chen
|
p. 62-64
|
|
|
|
|
|
Correspondence to editorial 3 on “Baveno Ⅵ-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”
|
Haiyu Wang, Jinjun Chen
|
p. 65-67
|
|
|
|
|
|
(Correspondence) Emerging evidence supports direct-acting antiviral therapy for HCC patients beyond the early stage : correspondence to editorial on “direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: a nationwide cohort study”
|
Teng-Yu Lee, Pei-Chien Tsai, Shou-Wu Lee, Ming-Lung Yu
|
p. 68-71
|
|
|
|
|
|
Correspondence to editorial on “GULP1 as a novel diagnostic and predictive biomarker in hepatocellular carcinoma”
|
Soon Sun Kim, Hyung Seok Kim, Jae Youn Cheong, Jung Woo Eun
|
p. 72-74
|
|
|
|
|
|
Correspondence to editorial on “CD36 promotes iron accumulation and dysfunction in CD8+ T cells via the p38-CEBPB-TfR1 axis in early-stage hepatocellular carcinoma”
|
Yifei Qin, Peng Lin, Huijie Bian, Zhi-Nan Chen, Jiao Wu
|
p. 75-78
|
|
|
|
|
|
Correspondence to editorial on “molecular classification of hepatocellular carcinoma based on zoned metabolic feature and oncogenic signaling pathway”
|
Tomoko Aoki, Naoshi Nishida, Masatoshi Kudo
|
p. 79-82
|
|
|
|
|
|
Correspondence to editorial 1 on “impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues”
|
Rui Huang, Mindie H. Nguyen
|
p. 83-84
|
|
|
|
|
|
Correspondence to editorial 2 on “impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues”
|
Rui Huang, Mindie H. Nguyen
|
p. 85-86
|
|
|
|
|
|
Correspondence to editorial on “risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease”
|
Hye Won Lee, Seung Up Kim
|
p. 87-89
|
|
|
|
|
|
Correspondence to editorial 1 on “MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation”
|
Tiantian Wang, Wenjie Huang, Limin Xia
|
p. 90-92
|
|
|
|
|
|
Correspondence to editorial 2 on “MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation”
|
Tiantian Wang, Wenjie Huang, Limin Xia
|
p. 93-95
|
|
|
|
|
|
(Correspondence) Advancing policy and practice in alcohol-associated liver disease and alcohol-attributable cancer : correspondence to the editorial on “sex disparities in alcohol-associated liver disease and subtype differences in alcohol-attributable cancers in the United States”
|
Pojsakorn Danpanichkul, Donghee Kim, Karn Wijarnpreecha, Amit G. Singal, Ju Dong Yang
|
p. 96-98
|
|
|
|
|
|
(Correspondence) Revisiting unmet needs in clinical research on directacting antiviral therapy for HCC patients : correspondence to letter to the editor on “direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: a nationwide cohort study”
|
Teng-Yu Lee, Pei-Chien Tsai, Shou-Wu Lee, Ming-Lung Yu
|
p. 99-102
|
|
|
|
|
|
Correspondence to letter to the editor on “GULP1 as a novel diagnostic and predictive biomarker in hepatocellular carcinoma”
|
Hyung Seok Kim, Soon Sun Kim, Jae Youn Cheong, Jung Woo Eun
|
p. 103-105
|
|
|
|
|
|
Reply to correspondence on “Baveno Ⅵ-SSM stratifies the risk of portal hypertension-related events in patients with HBV-related cirrhosis”
|
Mathias Jachs, Mattias Mandorfer
|
p. 106-108
|
|
|
|
|
|
(Reply to correspondence) Should direct-acting antiviral be considered for all patients with HCV-related hepatocellular carcinoma? : reply to correspondence on “direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: a nationwide cohort study”
|
Yan Ling Ong, Apichat Kaewdech, Yu Jun Wong
|
p. 109-111
|
|
|
|
|
|
(Reply to correspondence) GULP1 : new hope for hepatocellular carcinoma : reply to correspondence on “GULP1 as a novel diagnostic and predictive biomarker in hepatocellular carcinoma”
|
Yuhao Xie, Lu-Qi Cao, John Wurpel, Zhe-Sheng Chen
|
p. 112-114
|
|
|
|
|
|
Reply to correspondence on “molecular classification of hepatocellular carcinoma based on zoned metabolic feature and oncogenic signaling pathway”
|
Eun Ji Jang, Pil Soo Sung
|
p. 115-116
|
|
|
|
|
|
(Reply to correspondence) Advancing metabolic risk profiling in chronic hepatitis B : reply to correspondence on “metabolic health in antiviral era of chronic hepatitis B”
|
Shang-Chin Huang, Jia-Horng Kao
|
p. 117-118
|
|
|
|
|
|
Reply to correspondence 1 on “MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation”
|
Many Sze Man Chan, Terence Kin Wah Lee
|
p. 119-120
|
|
|
|
|
|
Reply to correspondence 2 on “MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation”
|
Ji Eun Han, Soon Sun Kim, Jae Youn Cheong, Jung Woo Eun
|
p. 121-124
|
|
|
|
|
|
Reply to correspondence 1 on “sex disparities in alcohol-associated liver disease and subtype differences in alcohol-attributable cancers in the United States”
|
Sung-Eun Kim
|
p. 125-127
|
|
|
|
|
대표어
한국학술지인용색인(NRF)
